A detailed history of Geode Capital Management, LLC transactions in Rallybio Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 244,986 shares of RLYB stock, worth $242,536. This represents 0.0% of its overall portfolio holdings.

Number of Shares
244,986
Previous 220,006 11.35%
Holding current value
$242,536
Previous $294,000 2.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.09 - $1.45 $27,228 - $36,221
24,980 Added 11.35%
244,986 $286,000
Q2 2024

Aug 09, 2024

SELL
$1.34 - $2.98 $401,520 - $892,933
-299,642 Reduced 57.66%
220,006 $294,000
Q1 2024

May 13, 2024

BUY
$1.25 - $2.4 $17,983 - $34,528
14,387 Added 2.85%
519,648 $961,000
Q4 2023

Feb 13, 2024

BUY
$1.91 - $4.39 $13,383 - $30,760
7,007 Added 1.41%
505,261 $1.21 Million
Q3 2023

Nov 13, 2023

BUY
$3.37 - $6.16 $16,455 - $30,079
4,883 Added 0.99%
498,254 $1.68 Million
Q2 2023

Aug 11, 2023

BUY
$4.31 - $8.89 $558,623 - $1.15 Million
129,611 Added 35.63%
493,371 $2.79 Million
Q1 2023

May 15, 2023

BUY
$4.37 - $8.75 $282,664 - $565,976
64,683 Added 21.63%
363,760 $2.08 Million
Q4 2022

Feb 13, 2023

BUY
$4.67 - $14.86 $174,466 - $555,154
37,359 Added 14.27%
299,077 $1.96 Million
Q3 2022

Nov 14, 2022

BUY
$7.54 - $14.56 $512,048 - $988,784
67,911 Added 35.04%
261,718 $3.79 Million
Q2 2022

Aug 12, 2022

SELL
$6.26 - $13.65 $157,895 - $344,293
-25,223 Reduced 11.52%
193,807 $1.46 Million
Q1 2022

May 13, 2022

BUY
$6.91 - $15.04 $725,473 - $1.58 Million
104,989 Added 92.06%
219,030 $1.53 Million
Q4 2021

Feb 11, 2022

BUY
$9.3 - $19.91 $409,925 - $877,592
44,078 Added 63.0%
114,041 $1.09 Million
Q3 2021

Nov 12, 2021

BUY
$10.83 - $23.4 $757,699 - $1.64 Million
69,963 New
69,963 $1.23 Million

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $31.8M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.